Clinical Trials Center, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China.
Institute of Medical Biology, Chinese Academy of Medical Sciences and Peking Union Medical College, Kunming, China.
J Hematol Oncol. 2023 Jul 18;16(1):75. doi: 10.1186/s13045-023-01457-x.
The mRNA-based therapeutics have become the hot spot of biopharmaceutical industries in recent years. The landscape of this area is expanding from infectious disease to cancer, which needs to be summarized to provide data supports for industries and research institutions. Based on the Trialtrove database, a total of 108 clinical trials from 1999 to 2021 were retrospectively analyzed. We have demonstrated that the clinical development of mRNA therapies against solid tumors is still at an early stage. There are evolutions in delivery systems from the dendritic cell to the lipid-based platform and in encoding strategies from the fixed tumor antigens to the personalized neoantigens. The adjuvant or maintenance therapy and the combination treatment with checkpoint inhibitors are becoming the major clinical development orientation.
mRNA 疗法近年来已成为生物制药行业的热点。该领域的格局正在从传染病扩展到癌症，这需要进行总结，为行业和研究机构提供数据支持。基于 Trialtrove 数据库，对 1999 年至 2021 年的 108 项临床试验进行了回顾性分析。我们表明，针对实体瘤的 mRNA 疗法的临床开发仍处于早期阶段。在递药系统方面，从树突细胞向基于脂质的平台发展，在编码策略方面，从固定的肿瘤抗原向个性化的新抗原发展。佐剂或维持治疗以及与检查点抑制剂的联合治疗正在成为主要的临床开发方向。
